AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

Amgen reported that both dazodalibep dosing regimens met the Phase 3 OASIZ-301 primary endpoint at Week 48, improving ESSDAI scores by 5.6 points (1,500 mg every four weeks) and 5.2 points (3,000 mg every 12 weeks), versus 3.8 points with placebo; differences were statistically significant. The every-four-week regimen also significantly improved both patient-reported dryness measures, with treatment-emergent adverse events, serious adverse events and discontinuations at similar rates across groups. Amgen plans to present these results and additional UPLIZNA, KRYSTEXXA and TAVNEOS data at ACR Convergence 2026; dazodalibep remains investigational.

Analysis

The investable signal is pipeline de-risking, not an immediate earnings revision. A positive Phase 3 result supports a potential Sjögren’s program, but the placebo-adjusted systemic score advantage is relatively modest and the reported dryness benefit is confined to the every-four-week regimen. Full conference data—especially endpoint hierarchy, missing-data handling, subgroup consistency and safety detail—will determine whether the result is robust enough to support a regulatory path and physician uptake. For diversified Amgen, even a successful launch would likely be a multi-year option rather than a near-term group-level growth driver.

The next material catalyst is OASIZ 303, expected in Q4 2026, which tests a different, symptom-heavy population; success there would broaden the addressable clinical profile, while failure would leave the program dependent on systemic-disease patients. A further second-order hurdle is that efficacy on trial scales must translate into payer coverage and routine-practice persistence in a heterogeneous, underdiagnosed disease. The UPLIZNA extension and KRYSTEXXA/TAVNEOS real-world presentations are incremental evidence, not clear new-label or revenue catalysts; observational findings should not be valued like controlled trial results. Near term, ACR detail may drive sentiment, but the broader AMGN valuation response should be limited absent a differentiated commercial forecast. The contrarian risk is treating statistical significance as proof of a large commercial opportunity before seeing full data and OASIZ 303.

Key Decisions for Investors

• Do not chase AMGN solely on this announcement; treat dazodalibep as pipeline optionality rather than a near-term earnings upgrade. Reassess after the full ACR dataset and verify endpoint multiplicity, discontinuations, subgroup results and any FDA-facing development plan.
• Set an alert for OASIZ 303’s expected Q4 2026 completion/readout. A result consistent with benefit in the symptom-heavy population would strengthen the franchise case; a miss would materially narrow the opportunity and falsify the broader-population thesis.
• For an existing AMGN position, retain exposure only in line with the wider portfolio thesis; avoid adding event-driven options before full data. The release provides no defensible price target or clear standalone trade given Amgen’s diversified earnings base.
• Treat UPLIZNA, KRYSTEXXA and TAVNEOS presentations as watch items, not incremental sales catalysts, unless data show a change in prescribing, persistence or guideline use. Verify whether evidence is controlled or observational and monitor safety concerns, particularly for TAVNEOS.